Drug intelligence / Profile preview

SB-313-xTZ

Development stage: Unknown
Lead developer: Sangamo Therapeutics
Modality: Zinc Finger Nucleases → Other Nucleases → Programmable Nucleases → Gene Editing → Gene Therapies

Overview

**SB-313-xTZ** is a ZFP Therapeutic (zinc finger protein-based therapy) developed by Sangamo BioSciences for the treatment of recurrent or refractory glioblastoma multiforme (GBM), an aggressive brain cancer with limited treatment options. It leverages Sangamo's proprietary zinc finger DNA-binding platform to enable targeted gene regulation or modification in tumor cells. The program received a Qualifying Therapeutic Discovery Project Grant of $244,479.25 from the IRS in 2010 and was noted to be in a Phase 1 clinical trial as part of Sangamo's oncology portfolio.[1][3][7][10]

Beyond the preview

Go deeper on SB-313-xTZ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB-313-xTZ.

Explore the full profile